Design Therapeutics (DSGN) Total Liabilities (2020 - 2026)

Design Therapeutics has reported Total Liabilities for 7 years, with the latest figure at $13.3 million in Q2 2026.

• Total Liabilities for Q2 2026 came in at $13.3 million, up 34.74% year-over-year; the trailing twelve-month figure through Jun 2026 was $13.3 million (up 34.74% YoY), and the FY2025 annual result was $13.7 million, up 37.05% from the prior year.
• Total Liabilities rose to $13.3 million in Q2 2026, from $12.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $14.9 million in Q3 2023 and troughed at $8.3 million in Q2 2024.
• A 5-year average of $11.6 million and a median of $11.9 million in 2023 frame the typical range for Total Liabilities.
• The widest annual swing landed in 2022, when Total Liabilities soared 203.78%; it then sank 43.78% in 2024.
• A 5-year view of Total Liabilities shows it stood at $13.8 million in 2022, then retreated by 13.53% to $12.0 million in 2023, then declined by 16.39% to $10.0 million in 2024, then surged by 37.05% to $13.7 million in 2025, then decreased by 3.13% to $13.3 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $13.3 million in Q2 2026, $12.4 million in Q1 2026, and $13.7 million in Q4 2025.